Trial Profile
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL) - A Randomised, Placebo Controlled Clinical Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Dec 2023
Price :
$35
*
At a glance
- Drugs Exenatide (Primary) ; Sodium-glucose transport protein inhibitors
- Indications Cardiovascular disorders; Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms EXSCEL
- Sponsors Amylin Pharmaceuticals; AstraZeneca; Bristol-Myers Squibb; Eli Lilly and Company
- 13 Nov 2023 Results assessing high throughput proteomic profiling performed using the SomaLogic SomaScan platform in 5473 patients with type 2 diabetes enrolled in the EXSCEL clinical trial, presented at the American Heart Association Scientific Sessions 2023.
- 01 Jun 2023 Results assessing the sex differences in the characteristics and outcomes in participants with type 2 diabetes, with or without cardiovascular disease, published in the Diabetes, Obesity and Metabolism.
- 31 Oct 2022 According to a SomaLogic media release, data from the trial will be presented at the American Heart Association Scientific Sessions 2022.